Pilot study of H-2 therapy in Parkinson’s disease: A randomized double-blind placebo-controlled trial
Read more:
DOI:
10.1002/mds.25375
DOI is the universal ID for this study.
This link will take you to the full study.
Abstract:
Background: Oxidative stress is involved in the progression of Parkinson's disease (PD). Recent studies have confirmed that molecular hydrogen (H₂) functions as a highly effective antioxidant in cultured cells and animal models. Drinking H₂-dissolved water (H₂-water) reduced oxidative stress and improved Parkinson's features in model animals.
Methods: In this a placebo-controlled, randomized, double-blind, parallel-group clinical pilot study, the authors assessed the efficacy of H₂ -water in Japanese patients with levodopa-medicated PD. Participants drank 1,000 mL/day of H₂-water or pseudo water for 48 weeks.
Results: Total Unified Parkinson's Disease Rating Scale (UPDRS) scores in the H₂-water group (n=9) improved (median, -1.0; mean ± standard deviation, -5.7 ± 8.4), whereas UPDRS scores in the placebo group (n=8) worsened (median, 4.5; mean ± standard deviation, 4.1 ± 9.2). Despite the minimal number of patients and the short duration of the trial, the difference was significant (P<0.05). Conclusions: The results indicated that drinking H₂-water was safe and well tolerated, and a significant improvement in total UPDRS scores for patients in the H₂-water group was demonstrated.
| Publish Year | 2013 |
|---|---|
| Country | Japan |
| Rank | Positive |
| Journal | Movement Disorders |
| Primary Topic | Brain |
| Secondary Topic | Parkinson's Disease |
| Model | Human |
| Tertiary Topic | Oxidative Stress |
| Vehicle | Water (Dissolved) |
| pH | Neutral |
| Application | Ingestion |
| Comparison | |
| Complement | Levodopa |